Stryker Corporation
Stryker Reports Strong Q3 2025 Financial Results
Summary
Stryker Corporation announced its third-quarter 2025 operating results, showing a 10.3% increase in net sales to $6.1 billion and a 9.5% rise in organic net sales. The company reported an operating income margin of 18.7% and adjusted operating income margin of 25.6%. Diluted EPS increased by 2.8% to $2.22, and adjusted diluted EPS rose by 11.1% to $3.19. Stryker also raised its full-year 2025 guidance for organic net sales growth to 9.8% to 10.2% and adjusted net earnings per diluted share to $13.50 to $13.60.
Profitelligence Alerts
Get alerts for SYK
Be first to know when Stryker Corporation files with the SEC.
Filing Categories
Advertisement
About Stryker Corporation
Stryker Corporation is a prominent player in the medical technology industry, known for its innovative solutions across healthcare sectors such as orthopedics, medical and surgical, and neurotechnology and spine. The company's purpose is to enhance patient care through its wide array of products, including surgical equipment and advanced medical devices. Stryker plays a critical role in the healthcare market by providing essential tools and technologies that assist in improving surgical precision and patient recovery processes. With a continuous focus on research and development, Stryker Corporation remains at the forefront of medical advancements, directly impacting hospitals, surgical centers, and healthcare providers globally. The company's extensive distribution network and partnerships with medical professionals ensure that its technologies contribute to improving health outcomes across diverse geographical regions.
Official SEC Documents
Advertisement